BACKGROUND:Patients with major depressive disorder (MDD) who fail to achieve complete remission with antidepressant therapy may benefit from augmentation therapy with an atypical antipsychotic. METHOD: A pooled analysis was performed on 2 identical 14-week studies (8-week prospective antidepressant therapy treatment phase followed by 6-week randomized double-blind phase) evaluating the efficacy of adjunctive aripiprazole (2-20 mg/day) in DSM-IV-TR-defined MDD patients with an inadequate response to antidepressant therapy. Primary efficacy endpoint was the mean change in Montgomery-Asberg Depression Rating Scale (MADRS) total score from end of the prospective phase (week 8) to end of randomized phase (week 14, last observation carried forward). Subgroup analyses were performed. The key secondary endpoint was mean change in Sheehan Disability Scale (SDS) mean score. RESULTS: At endpoint, mean change in MADRS total score was significantly greater with adjunctive aripiprazole (-8.7) than with adjunctive placebo (-5.7; p < .001). Except for a differential treatment-by-sex interaction, change in MADRS total scores were consistently greater with adjunctive aripiprazole than with adjunctive placebo, regardless of race, age, episode duration, prior antidepressant therapy response, number of historical treatment failures, severity of depressive symptoms, and antidepressant. At endpoint, MADRS remission rates were significantly greater with adjunctive aripiprazole than with placebo (25.7% vs. 15.4%; p < .001). Adjunctive aripiprazole also demonstrated significantly greater improvements in mean change from baseline in SDS total score than adjunctive placebo (-1.2 vs. -0.6; p = .001). CONCLUSION: Augmentation of antidepressant therapy with the atypical antipsychotic aripiprazole resulted in significant efficacy benefits across a range of subgroups of patients with MDD. Further study of a treatment-by-sex interaction is needed. TRIAL REGISTRATION: www.clinicaltrials.gov Identifiers: NCT00095823 and NCT00095758.
RCT Entities:
BACKGROUND:Patients with major depressive disorder (MDD) who fail to achieve complete remission with antidepressant therapy may benefit from augmentation therapy with an atypical antipsychotic. METHOD: A pooled analysis was performed on 2 identical 14-week studies (8-week prospective antidepressant therapy treatment phase followed by 6-week randomized double-blind phase) evaluating the efficacy of adjunctive aripiprazole (2-20 mg/day) in DSM-IV-TR-defined MDDpatients with an inadequate response to antidepressant therapy. Primary efficacy endpoint was the mean change in Montgomery-Asberg Depression Rating Scale (MADRS) total score from end of the prospective phase (week 8) to end of randomized phase (week 14, last observation carried forward). Subgroup analyses were performed. The key secondary endpoint was mean change in Sheehan Disability Scale (SDS) mean score. RESULTS: At endpoint, mean change in MADRS total score was significantly greater with adjunctive aripiprazole (-8.7) than with adjunctive placebo (-5.7; p < .001). Except for a differential treatment-by-sex interaction, change in MADRS total scores were consistently greater with adjunctive aripiprazole than with adjunctive placebo, regardless of race, age, episode duration, prior antidepressant therapy response, number of historical treatment failures, severity of depressive symptoms, and antidepressant. At endpoint, MADRS remission rates were significantly greater with adjunctive aripiprazole than with placebo (25.7% vs. 15.4%; p < .001). Adjunctive aripiprazole also demonstrated significantly greater improvements in mean change from baseline in SDS total score than adjunctive placebo (-1.2 vs. -0.6; p = .001). CONCLUSION: Augmentation of antidepressant therapy with the atypical antipsychotic aripiprazole resulted in significant efficacy benefits across a range of subgroups of patients with MDD. Further study of a treatment-by-sex interaction is needed. TRIAL REGISTRATION: www.clinicaltrials.gov Identifiers: NCT00095823 and NCT00095758.
Authors: A A Nierenberg; B R Keefe; V C Leslie; J E Alpert; J A Pava; J J Worthington; J F Rosenbaum; M Fava Journal: J Clin Psychiatry Date: 1999-04 Impact factor: 4.384
Authors: Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava Journal: Am J Psychiatry Date: 2006-01 Impact factor: 18.112
Authors: Michael E Thase; Sara A Corya; Olawale Osuntokun; Michael Case; David B Henley; Todd M Sanger; Susan B Watson; Sanjay Dubé Journal: J Clin Psychiatry Date: 2007-02 Impact factor: 4.384
Authors: J Craig Nelson; Michael E Thase; Madhukar H Trivedi; Maurizio Fava; Jian Han; Quynh Van Tran; Andrei Pikalov; Ying Qi; Berit X Carlson; Ronald N Marcus; Robert M Berman Journal: Prim Care Companion J Clin Psychiatry Date: 2009
Authors: L L Judd; H S Akiskal; J D Maser; P J Zeller; J Endicott; W Coryell; M P Paulus; J L Kunovac; A C Leon; T I Mueller; J A Rice; M B Keller Journal: J Affect Disord Date: 1998-09 Impact factor: 4.839
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: Stephen F Smagula; Meredith L Wallace; Stewart J Anderson; Jordan F Karp; Eric J Lenze; Benoit H Mulsant; Meryl A Butters; Daniel M Blumberger; Breno S Diniz; Francis E Lotrich; Mary Amanda Dew; Charles F Reynolds Journal: J Psychiatr Res Date: 2016-07-07 Impact factor: 4.791
Authors: George I Papakostas; Maurizio Fava; Lee Baer; Michaela B Swee; Adrienne Jaeger; William V Bobo; Richard C Shelton Journal: Am J Psychiatry Date: 2015-06-18 Impact factor: 18.112
Authors: David L Dunner; Kimberly K Laubmeier; George Manos; Robert A Forbes; Ross A Baker; Robert M Berman Journal: Prim Care Companion CNS Disord Date: 2012-11-22
Authors: G M Goodwin; P M Haddad; I N Ferrier; J K Aronson; Trh Barnes; A Cipriani; D R Coghill; S Fazel; J R Geddes; H Grunze; E A Holmes; O Howes; S Hudson; N Hunt; I Jones; I C Macmillan; H McAllister-Williams; D R Miklowitz; R Morriss; M Munafò; C Paton; B J Saharkian; Kea Saunders; Jma Sinclair; D Taylor; E Vieta; A H Young Journal: J Psychopharmacol Date: 2016-03-15 Impact factor: 4.153